Arms’ Length: Bayer Sees Progress in Hands-Off R&D Approach

This month, Bayer tripled its peak sales forecast for the oral androgen receptor inhibitor, from €1 billion ($1.1 billion) to €3 billion ($3.4 billion), following positive clinical data presented February 17 at the 2022 American Society of Clinical Oncology (ASCO) GU Cancers Symposium. The data showed that Nubeqa plus androgen deprivation therapy (ADT) and docetaxel reduced the risk of death by more than 30% in patients with mHSPC compared to ADT plus docetaxel . . .

The post Arms’ Length: Bayer Sees Progress in Hands-Off R&D Approach appeared first on GEN – Genetic Engineering and Biotechnology News.

Source